Atellas Pharma, Inc. last week tendered an offer for all shares of Ocata Therapeutics, Inc.
Atellas has offered $8.50 per share for all issued and outstanding stock through its indirect, wholly owned subsidiary Laurel Acquisition Inc. The offer, including the offer to purchase, letter of transmittal and other documents, was filed with the Securities and Exchange Commission (SEC), on November 19. With a successful completion of the tender offer, Laurel and Ocata will merge. Ocata will then be an indirect, wholly owned subsidiary of Astellas. The Tender Offer expires at midnight EST on December 17.
Tokyo-based Astellas Pharma, Inc. focuses on pharmaceutical products, prioritizing immunology, nephrology, neuroscience and oncology. The headquarters for the Americas, Astellas US, LLC., and its divisions Astellas Pharma US, Inc.; Astellas Pharma Global Development, Inc.; Astellas Scientific and Medical Affairs and Astellas US Technologies, Inc. are based in Northbrook, Illinois and employ more than 3,000 people.
Ocata Therapies, Inc., focuses on the development of new therapies in replacing or regenerating human cells, tissues or organs. The primary research and development is focused on treating eye diseases and disorders. These include treatments for macular degeneration, diabetic retinopathy, retinitis pigmentosa, uveitis and other damage to the retina.
Alerts Sign-up